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Zu¨hre Kaya,1 Daniel J. Weiner,2 Deniz Yilmaz,3 Jason Rowan,4 Rakesh K. Goyal4Pulmonary complications (PC) remain a significant barrier to the success of allogeneic blood and marrow trans-
plantation (BMT). Pretransplant pulmonary function tests (PFTs) have been correlated with risk of early respi-
ratory failure andmortality in adult BMTrecipients. There is limited data on their relationship to posttransplant
outcomes in pediatric patients. We sought, in pediatric allo-BMTrecipients (1) to analyze the spectrum of in-
fectious and noninfectious PCs, (2) to evaluate the prevalence and course of PFTabnormalities before and after
transplant, and (3) to correlate pretransplant PFT findings with patient outcomes, specifically risk of PC, respi-
ratory failure, and death.We conducted a retrospective review of PC in all patients who underwent allo-BMTat
Children’s Hospital of Pittsburgh during 1996 to 2006. PFTs were performed in children 6 years and older pre-
transplant, 3, 6, 12, and 24 months after transplant. PCs occurring within 100 days of BMTwere considered
early. One hundred ten consecutive children who underwent allo-BMTwere included (median age5 9.7 years;
67males, 43 females). Seventy-five of 110 patients had 370 PFT studies performed; 62 of 73 patients.6 years of
age (85%) underwent PFT studies pre-BMT. There was a significantly higher risk of early respiratory failure in
patients with reduced pretransplant forced expiratory volume in 1 second (FEV1) (P5 .0001, odds ratio [OR]
5.1) or forced vital capacity (FVC) (P5 .0001, OR 8.5). Forty-three of 110 (39%) patients required mechanical
ventilation, and in 30 episodes (70%), patients remained ventilator-dependent until time of death. Posttrans-
plant, we observed statistically significant reductions in FEV1, FVC, total lung capacity (TLC), and diffusing ca-
pacity of the lungs (DLco) at 3 months post-BMTand similar reductions at 6 months post-BMTexcept for DLco
(not significant). Between 12 and 24 months, FEV1, FVC, TLC, and DLco improved significantly from earlier
declines post-BMT; however FEV1 and FVC remained significantly below pretransplant values. At a median fol-
low-up of 5.5 (1.6-11.6) years, 58 of 110 (53%) patients were surviving. The majority of the patients who died
from transplant-related complications suffered from 1 or more PCs (31/32, 97%). Early PC was associated with
over 4-fold reduction in probability of survival at 10 years (8/44, 18% with early PC versus 50/66, 76% without
early PC). On multivariate analysis, risk of death was significantly associated with high-risk disease status (P 5
.015; hazard ratio [HR]5 2.5), unrelated donor (P5 .03; HR5 2.1), early PC (P5 .0001; HR5 7.7) and path-
ogen identification (P 5 .02; HR 5 2.7). These results suggest that, in children undergoing allo-BMT (1) com-
promised pretransplant lung function is significantly correlated with risk of early respiratory failure but not of
overall survival (OS), (2) reductions in lung volumes and diffusion capacity are common 3- to 6-month post-
transplant with partial recovery by 12 to 24months, (3) there is high mortality following mechanical ventilation,
and (4) early PCs are associated with significantly worse OS.
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Allogeneic blood and marrow transplantation
(allo-BMT) has been successfully used to treat malig-
nant and nonmalignant diseases in both adults and
children. Despite application of stringent HLA match-
ing criteria and advances in supportive care, success
of transplantation is frequently compromised by infec-
tious and noninfectious pulmonary complications
(PCs) [1-3]. PCs have been reported in 40% to 60%
of adult BMT recipients, and may contribute to death
in over one-third of these cases; similar data in children
are limited, and natural history of PCs remains incom-
pletely understood [4-7].
Pulmonary function tests (PFTs) are widely per-
formed before BMT to screen for underlying respira-
tory abnormalities and to provide baseline lung
function measurements. Previous studies have exam-
ined the predictive value of baseline PFTs for posttrans-
plant complications [8-10]. However, the majority of
published data is on adults, includes auto- as well as
allo-BMT patients, and findings are not consistent.
Recently, Parimon and colleagues [11] published data
from a retrospective analysis of a large cohort of adult
allogeneic BMT recipients. Their results showed that
compromised pretransplant lung function significantly
contributes to risk of early respiratory failure and mor-
tality. There are limited data on their relationship in
pediatric patients.
In this study, we undertook a retrospective review
of PCs in all patients who underwent allo-BMT at Chil-
dren’s Hospital of Pittsburgh over a 10-year period. We
analyzed the spectrum of infectious and noninfectious
PCs and evaluated serial PFTs before and after trans-
plant. We hypothesized that pretransplant PFTs would
correlate with development of pulmonary complica-
tions and survival. We also sought to examine the
impact of early respiratory failure on posttransplant
outcomes, and relationship between PCs and death.PATIENTS AND METHODS
The study was approved by the institutional review
board of the University of Pittsburgh. Clinical, labora-
tory, pathology, and imaging data were retrieved for all
consecutive patients who underwent allo-BMT at
Children’s Hospital of Pittsburgh between October
10, 1996, and September 1, 2006.Definition of PCs
PC in a BMT recipient was defined as development
of 1 or more of the following: new or persistent pulmo-
nary infiltrates on chest radiograph or chest computed
tomography (CT) scan; signs of lower respiratory tract
disease including wheezing, increased work of breath-
ing, crackles on auscultation of chest; hemoptysis;hypoxemia (arterial oxygen saturations \90% on
room air) in the absence of primary cardiogenic etiol-
ogy [1,2].Classification of PCs
1. Early versus late: PCs that occur within 100 days
of BMT were considered ‘‘early’’ and those after
100 days were considered ‘‘late.’’a. Patients were defined as having developed early
respiratory failure if they required mechanical
ventilation for a nonelective reason within 100
days after transplant.2. Infectious versus noninfectious:
a. Infectious or presumably infectious: if a patho-
genic microbial agent was detected from bron-
choalveolar lavage (BAL), lung biopsy, nasal
wash, tracheal aspirate, autopsy, or no pathogen
agent was detected, but clinical findings were
highly suggestive of infection (high fever, local-
ized pneumonia by radiographic studies, con-
comitant positive blood cultures for common
agents for pneumonia), the PC was defined as
infectious or presumably infectious. Invasive
fungal infections were recorded based on pub-
lished criteria from European Organization
for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group [12]. The
presence of a pulmonary copathogen was de-
fined as the isolation of more than 1 pathogenic
bacterial species, fungal species (such as Asper-
gillus fumigatus), or viruses from the same BAL
or lung biopsy specimen [13].
b. Noninfectious: clinical descriptions from
Michelson et al. [1] and Gower et al. [14] were
used for classification of noninfectious and late
complications. Briefly,
i. Idiopathic pneumonia syndrome (IPS)—
dyspnea, nonproductive cough, hypoxemia,
nonlobar radiographic infiltrates in absence
of lower respiratory tract infection or heart
failure [15,16].
ii. Pulmonary edema—dyspnea, nonproduc-
tive cough, hypoxemia, nonlobar radio-
graphic infiltrates because of heart failure.
iii. Pulmonary hemorrhage—bleeding from
endotracheal tube with infiltrate on chest
X-ray, bleeding seen at bronchoscopy,
X-ray infiltrate with drop in Hgb, or occult
hemorrhage that was shown by hemosid-
erin containing alveolar macrophages in
BAL or biopsy.
iv. Bronchiolitis obliterans—chronic lower
airway obstruction, cough, dyspnea, small
fixed airway obstruction on PFTs, mosaic
Biol Blood Marrow Transplant 15:817-826, 2009 819Lung Function in Pediatric Allogeneic BMT Recipientsperfusion on high resolution chest CT, and
when biopsies were performed histopatho-
logic findings of organizing exudates with
plugs of granulation and connective tissue
in the distal airway.
v. Bronchiolitis obliterans organizing pneu-
monia (BOOP)—diagnosed by histology.
Characteristic findings include polypoid
endobronchial myxoid fibroblastic tissue
masses filling the lumens of terminal and
respiratory bronchioles and extending into
alveolar ducts and alveoli, representing an
organizing pneumonia.Evaluation of Risk Factors
This included age at BMT; disease status prior to
conditioning (standard risk—acute leukemia or lym-
phoma in complete remission (CR)1 or CR2, CMV
in first chronic phase; high-risk—acute leukemia or
lymphoma in relapse or $CR3, CML beyond first
chronic phase, myelodysplastic syndrome (MDS), or
secondary acute myelogenous leukemia (AML) as previ-
ously defined [17]); history of pretransplant pulmonary
disease; HLA match; donor-recipient CMV status; con-
ditioning regimen; graft-versus-host disease (GVHD)
prophylaxis; and acute GVHD (aGVHD). Posttrans-
plant outcomes including timing, type, severity, and
course of PCs, and GVHD and chronic GVHD
(cGVHD) were abstracted. All chest X- ray and CT
scan reports; microbiology and pathology results of
BAL samples, nasal wash, tracheal aspirate, lung biop-
sies, and autopsies were reviewed.Pulmonary Function Studies
PFTs were performed in children 6 years and older
pretransplant, 3, 6, 12, and 24 months after transplant
and at other time points when clinically indicated.
Spirometry, body plethysmography, and diffusing
capacity were performed in the Pulmonary Function
Laboratory of Children’s Hospital of Pittsburgh by
a certified technician following the American Thoracic
Society/European Respiratory Society Guidelines [18].
Equipment utilized included the Sensormedics 2100
and the Sensormedics V-Max 22 with Autobox 6200
(Sensormedics Co., Yorba Linda, CA).
PFT study consisted of spirometry before and after
bronchodilator, lung volumes, and diffusion capacity.
Total lung capacity (TLC), forced vital capacity (FVC),
forced expiratory volume in 1 second (FEV1), FEV1/
FVC ratio, and carbon monoxide diffusing capacity
of the lungs (DLco) were included for this analysis
[19-22]. Actual values were normalized for sex and
height according to age-sex-race specific reference
equations. Lung volumes in African Americans were
adjusted with a fixed (0.85) correction. The DLco wascorrected for hemoglobin content (DLcoc) if a mea-
surement was available within the prior 30 days.
PFT measurements were converted to a percentage
of the predicted value, and a standard deviation score.
Using this normalization, FVC, FEV1, TLC, FEV1/
FVC, and DLco were categorized as normal (.80%)
or reduced (#80%) [23-25].
Statistical Methods
Statistical analyses were performed using SPSS 11, 5
(SPSS Inc., Chicago, IL), and P values of\.05 were
considered statistically significant. Changes in PFTs
from pretransplant values were performed using the
Wilcoxon test. Mann Whitney-U test was used to com-
pare the changes in PFTs between PC versus no PC
groups. Categoric data were compared by chi-squared
and Fisher exacts tests to study the relationship between
covariates and PFT abnormalities. Survival rates were
estimated by the Kaplan-Meier method. For multivari-
ate analysis, clinical risk factors with a value of P# .1 on
univariate analysis were included. Cox proportional
hazards regression model was used in multivariate anal-
ysis to identify risk factors associated with mortality. Re-
sults are presented as hazard ratio (HR) with 95%
confidence intervals (CIs) and significance.RESULTS
From October 10, 1996, to September 1, 2006, 110
patients underwent 114 allo-BMT at Children’s Hospi-
tal of Pittsburgh. One hundred two of 110 (93%) pa-
tients underwent ablative conditioning patients
received reduced-intensity conditioning (RIC) in 11 of
114 transplants. Median length of follow-up is 5.5 years
(1.6–11.6 years). Median age at BMT was 9.7 years (0.3-
23.3 years). There were 67 (61%) males and 43 (39%) fe-
males. Ninety-one percent of transplants were for
malignant diseases; 72% patients were high risk; 57%
donors were unrelated; stem cell sources included BN
73%, cord blood 23%, and peripheral blood (PBSC)
4%; 22% grafts were T cell depleted in vitro; 58% pa-
tients developed aGVHD and 27% of surviving patients
developed cGVHD.
Salient patient characteristics are summarized in
Table 1. HLA mismatched transplants (18/31; 58%)
were associated with greater risk of early PCs compared
with HLA matched transplants (26/79; 33%)(P5 .027).
No significant relationship was found among other
clinical characteristics and occurrence of early PCs.
Pretransplant Pulmonary Disease
Forty-two of 110 (38%) patients had history of
lower respiratory tract infection (LRTI) pretransplant.
Sixteen of 104 (15%) patients had known history of
asthma. Ten patients underwent mechanical ventila-
tion pre-BMT; 9 of 10 had mechanical ventilation
Table 1. Characteristics of the Allotransplant Recipients with and without Early Pulmonary Complications (PC)
With Early PCs* (n 5 44) Without Early PCs* (n 5 66) Total (n 5 110)
Age at BMT (years) median (range) 10.3 (0.3-23.3) 9.5 (0.5-20.1) 9.7 (0.3-23.3)
Sex (female/male) 16/28 27/39 43/67
Disease status
Standard risk 11 (25.0%) 26 (39.4%) 37 (33.6%)
High risk 33 (75.0%) 40 (60.6%) 73 (66.4%)
Prior pulmonary disease
Yes 21 (47.7%) 36 (54.5%) 57 (51.8%)
No 23 (52.3%) 30 (45.5%) 53 (48.2%)
Donor type
HLA matched 26 (59.1%)* 53 (80.3%)* 79 (71.8%)
HLA mismatch 18 (40.9%)* 13 (19.7%)* 31 (28.2%)
CMV status (%)
Host/donor/both seropositive 23 (52.3%) 24 (36.4%) 47 (42.7%)
Both seronegative 21 (47.7%) 42 (63.6%) 63 (57.3%)
Conditioning regimen (%)
TBI-based 30 (68.2%) 37 (56.1%) 67 (60.9%)
Chemotherapy-based 14 (31.8%) 29 (43.9%) 43 (39.1%)
GVHD prophylaxis (%)
Methotrexate-containing 23 (52.3%) 40 (60.6%) 63 (57.3%)
No methotrexate 21 (47.7%) 26 (39.4%) 47 (42.7%)
Acute GVHD
Yes 28 (63.6%) 36 (54.5%) 64 (58.2%)
No 16 (36.4%) 30 (45.5%) 46 (41.8%)
GVHD indicates graft-versus-host disease; BMT, blood and marrow transplantation; CMV, cytomegalovirus; TBI, total body irradiation.
*Differences between the 2 groups were not statistically significant except for HLA match versus mismatch donor (P 5 .027).
Table 2A. Microbiological Yield
Category Pathogen Number Total Comment
Bacterial 15
Staph aureus 3 MRSA (1)
Coagulase Negative
Staphylococcus
2
Enterobacter 2
Enterococcus 2
Klebsiella 2
Streptococcus 2
E. coli 1
Citrobacter 1
Fungal 14
Aspergillus 9
Candida 2
Fusarium 1
Rhizopus 1
Pneumocystis jiroveci 1
Viral 9
Parainfluenza 2 1 addl.
case -URTI only
CMV 2
HHV-6 1
HSV 1
RSV 1 1 addl.
case - URTI only
Adenovirus 1
Influenza 1
Mycobacterial 3
MAI 3
Total 41
MRSA indicates methicillin-resistant Staphylcoccus aureus; URTI, upper
respiratory tract infection; CMV, cytomegalovirus; RSV, respiratory syn-
cytial virus; HSV, herpes simplex virus; HHV-6, human herpes virus 6;
MAI, Mycobacterium avium intracellulare.
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prior lung radiation; 9 patients had received prior cra-
niospinal radiation therapy. Three of 3 patients with
sickle cell disease had prior history of recurrent acute
chest syndrome. Three patients had history of sleep
apnea. One patient suffered from longstanding bron-
chiectasis and chronic respiratory failure.
PC
Eighty-one of 110 (74%) patients developed 1 or
more PCs. These included 53 patients with LRTI
and 31 with noninfectious PC episodes; 3 patients
developed both infectious and noninfectious PCs at
different timepoints posttransplant. Forty-four of
110 (40%) patients developed early PCs (within 100
days posttransplant). Median time to onset of early
PCs was 29 days (3-98 days) and of late PCs 350 days
(102-2591 days) post-BMT.
Infectious PCs
Fifty-three of 110 (48%) patients had 56 episodes of
LRTIs. Thirty of 56 (54%) episodes in 29 patients were
found to have microbiologic/histopathologic evidence
of infection. Pathogens (41) were demonstrated from
tracheal aspirate or BAL (32), lung biopsy or autopsy (5),
nasopharyngeal secretions (1; parainfluenza), skin biopsy
(1; aspergillus), liver biopsy (1; aspergillus) and blood
culture (1; Mycobacterium avium-intracellulare [MAI])
(Table 2A). In 9 of 29 (31%) cases there were 2 to 3 pul-
monary copathogens identified from the same BAL or
lung biopsy sample; 5 of 9 cases had 1 or more fungal co-
pathogens (Aspergillus 1 E. coli 1 CMV; Aspergillus 1
Fusarium 1 Rhizopus; Aspergillus 1 Citrobacter; Candida1HSV1Coagulase-negativeStaphylococcus;Enterococcus
1 Coagulase-negative Staphylococcus 1 Parainfluenza;
Candida1Klebsiella;Klebsiella1HHV-6; MAI1Entero-
coccus, and Enterobacter1 Staphylococcus aureus). Sinusitis
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(9) and with radiologic findings (16); in 8 of 25 cases,
there was no associated LRTI.BAL
Thirty-eight (35%) patients underwent 41 BAL
procedures post-BMT. Twenty of 44 (45%) patients
with early PC and 18 of 37 (49%) patients with late
PCs underwent BAL procedure. Thirteen of these
procedures (32%) yielded 23 pathogens. One patient
was diagnosed with relapsed AML from BAL sample.
Ten of 38 (26%) patients who underwent BAL were
surviving compared to 48 of 72 (67%) of those who
did not undergo the procedure. Eight of 29 (28%) pa-
tients with pathogen identification were surviving ver-
sus 50 of 81 (62%) who did not (multivariate P 5 .02;
HR 5 2.7, 95% CI 5 1.5-4.8) (Table 3).Noninfectious PCs
Thirty-one of 110 (28%) patients developed 1 or
more noninfectious PCs (Table 2B). These included:
IPS (26 episodes in 25 patients)—associated diagnoses
were veno-occlusive (VOD) (9), multiorgan failure (7),
and antithymocyte globulin (ATG) reaction (1); car-
diogenic pulmonary edema (2); pleural effusion (23);
pulmonary hemorrhage (15); air leak (9); reactive air-
way disease (10); bronchiectasis (4), bronchiolitis oblit-
erans (6), BOOP (4); and others (7). IPS was
a contributing cause of death in 14 of 25 cases (56%).Table 2B. Noninfectious PCs
Idiopathic pneumonia
syndrome
26 Associated diagnoses—VOD (9),
multiorgan failure (7),
and ATG reaction (1)
Pleural effusion 23 1 malignant
Pulmonary hemorrhage 15
Reactive airway disease 10
Air leak 9
Bronchiolitis obliterans 6 Diagnosis made by HRCT
and PFT (3), biopsy (1),
and at autopsy (2)
BOOP 4 Diagnosed at autopsy (4)
with parainfluenza (1),
HSV 1 (1), enterococcus (1),
and MRSA (1) on cultures
Bronchiectasis 4
Cardiogenic pulmonary
edema
2
Interstitial fibrosis 2
Chest wall weakness 1
Chronic interstitial
lung Disease
1
Hemothorax 1
Hypersensitivity pneumonitis 1
Pleural fibrosis 1
VOD indicates veno-occulsive disease; BOOP, Bronchiolitis obliterans
organizing pneumonia; HSV, herpes simplex virus; MRSA, methicillin-
resistant Staphylcoccus aureus; HRCT, high-resolution chest computed
tomography; PFT, pulmonary function test; PC, pulmonary complication.Mechanical Ventilation
Forty-three of 110 (39%) patients required mechan-
ical ventilation, 1 twice. Indications for mechanical ven-
tilation included: LRTI (16), sepsis and multiorgan
failure (MOF) (16), pulmonary hemorrhage (15), IPS
(8), VOD and MOF (6), late noninfectious PCs and re-
spiratory failure (3), heart failure (2), and other (4; intra-
venous immunoglobulin (IVIG) anaphylaxis 1, AML of
lungs 1, seizure 1, and hypertensive encephalopathy 1).
Patients were successfully extubated in 13/44 episodes
(30%) with median 2 (10.3 6 17.7) days of mechanical
ventilation, whereas in 30 episodes (70%), patients re-
mained ventilator-dependent with median 10 (17.5 6
27.1) days of mechanical ventilation till time of death;
this difference in days of mechanical ventilation was
not statistically significant (P5 .62).Survival
At a median follow-up of 5.5 years (1.6-11.6),
58 of 110 (53%) patients were surviving. Ten-year
probability of overall survival (OS) is 76% (95% CI
5 66.5-85.1) for those without early PC versus 18%
(95% CI 5 9.9-27.3) for those with early PC (P 5
.0001) (Figure 1).
There were 52 deaths among 110 children (47%);
32 of the 52 (62%) deaths were because of transplant-
related complications and 20 of 52 (38%) because of
disease relapse. Majority of patients who died from
transplant-related complications suffered from 1 or
more PC (31/32, 97%).
On univariate analysis, OS was significantly associ-
ated with high-risk disease status, unrelated donor,
total body irradiation (TBI)-containing regimen, and
presence of early PC, but not with HLA match, any
PC, aGVHD, or cGVHD. On multivariate analysis,
risk of death was significantly associated with high-
risk disease status (P 5 .015; HR 5 2.5), unrelated
donor (P5 .03; HR 5 2.1), early PC (P5 .0001;
HR 5 7.7), and pathogen identification (P 5 .02;
HR 5 2.7) (Table 3).Pulmonary Function Tests
In all, 75 of 110 patients had 370 PFT studies per-
formed.Pretransplant PFTs
Sixty-two of 73 patients $6 years of age (85%)
underwent PFT studies pre-BMT. Twelve of 62
(19%) of the patients had reduced FVC, 12/62 (20%)
reduced FEV1, 8 of 62 (13%) reduced FEV1/FVC ra-
tio, 4 of 55 (9%) reduced TLC, and 29 of 50 (58%) re-
duced DLco pretransplant (Table 4). Isolated
reduction in DLco was the most common PFT abnor-
mality, observed in 18 of 50 patients (36%).
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Figure 1. Ten-year probabilities of OS after allo-BMT by occurrence of early PC.
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Patients with reduced pretransplant FEV1 or FVC
were significantly more likely to develop early respira-
tory failure (FEV1P5 .0001, OR5 5.1, 95% CI5 1.3-
19.8; FVC P 5 .0001, OR 5 8.5, 95% CI 5 2.1-36.4)
leading to mechanical ventilation with high mortality
rates in ventilated patients, as described under the
Mechanical Ventilation section. However, pretrans-
plant PFTs were not significantly correlated to risk of
PC or OS.Table 3. Association of Clinical Risk Factors and Survival
Variable Total n Nonsurvivors n (%) Univ
Disease status at BMT
Standard risk 37 9 (24%)
High risk 73 43 (59%)
HLA
Matched 79 33 (42%)
Mismatched 31 19 (61%)
Donor
Related 46 14 (30%)
Unrelated 64 38 (59%)
Conditioning regimen
TBI containing 67 40 (60%)
Non-TBI containing 43 12 (28%)
PC
Yes 81 43 (53%)
No 29 9 (31%)
Early PC
Yes 44 36 (82%)
No 66 16 (24%)
Acute GVHD
Yes 64 35 (55%)
No 46 17 (37%)
Chronic GVHD
Yes 30 14 (47%)
No 80 38 (48%)
Pathogen identification
Yes 29 21(72%)
No 81 31(38%)
CI indicates confidence interval; GVHD, graft-versus-host disease; PC, pulmo
transplantation.Posttransplant PFTs
PFT studies posttransplant showed 36%, 46%,
30%, and 77% of patients with FVC, FEV1, TLC,
and DLco abnormalities at 3 months, respectively,
and 42%, 49%, 27%, 75%, of patients with FVC,
FEV1, TLC, and DLco abnormalities at 6 post-
BMT, respectively (Table 4 and Figure 2). Between
12 and 24 months, PFT abnormalities tended to im-
prove. A longitudinal analysis was performed on 20 pa-
tients for whom complete PFT data was availableariate P Value Multivariate P Value Hazards Ratio (95% CI)
.001 .015 2.5 (1.2-5.4)
.10
.005 .03 2.1 (1.1-4.3)
.002 .32
.06
.0001 .0001 7.7 (3.7-16.1)
.10
.93
.001 .02 2.7 (1.5-4.8)
nary complication; TBI, total body irradiation; BMT, blood and marrow
Table 4. PFT Findings
Pre-BMT 3 Months 6 Months 12 Months 24 Months 36 Months 48 Months >60 Months
FVC n 5 62 n 5 46 n 5 43 n 5 37 n 5 26 n 5 15 n 5 10 n 5 8
Normal 50 (81%) 30 (64%) 25 (58%) 27 (73%) 21 (81%) 13 (86%) 8 (80%) 7 (87%)
Reduced 12 (19%) 15 (36%) 18 (42%) 10 (27%) 5 (19%) 2 (14%) 2 (20%) 1 (13%)
FEV1 n 5 62 n 5 46 n 5 43 n 5 37 n 5 26 n 5 15 n 5 10 n 5 8
Normal 50 (80%) 25 (54%) 22 (51%) 24 (65%) 17 (65%) 10 (67%) 7 (70%) 6 (75%)
Reduced 12 (20%) 21 (46%) 21 (49%) 13 (35%) 9 (35%) 5 (33%) 3 (30%) 2 (25%)
FEV1/FVC n 5 62 n 5 46 n 5 43 n 5 36 n 5 25 n 5 14 n 5 8 n 5 7
Normal 54 (87%) 35 (76%) 32 (74%) 29 (80%) 22 (88%) 12 (86%) 7 (88%) 5 (72%)
Reduced 8 (13%) 11 (24%) 11 (26%) 7 (20%) 3 (12%) 2 (14%) 1 (12%) 2 (28%)
TLC n:55 n:40 n:37 n:28 n:20 n:9 n:5 n:7
Normal 50 (91%) 28 (70%) 27 (73%) 22 (80%) 19 (95%) 8 (89%) 5 (100%) 6 (86%)
Reduced 4 (9%) 12 (30%) 10 (27%) 6 (20%) 1 (5%) 1 (11%) — 1 (14%)
DLco n 5 50 n 5 35 n 5 32 n 5 26 n 5 20 n 5 17 n 5 7 n 5 4
Normal 21 (42%) 8 (23%) 8 (25%) 9 (35%) 10 (50%) 10 (59%) 4 (57%) 3 (75%)
Reduced 29 (58%) 27 (77%) 24 (75%) 17 (65%) 10 (50%) 7 (41%) 3 (43%) 1 (25%)
PFT indicates pulmonary function test; BMT, blood and marrow transplantation; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second;
DLco, diffusing capacity of the lungs.
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plant (Table 5). It confirmed the findings observed in
the entire cohort with statistically significant reduc-
tions in FEV1, FVC, TLC, and DLco at 3 months
post-BMT, and similar reductions at 6 months post-
BMT except for DLco (not significant). Between 12
and 24 months, FEV1, FVC, TLC, and DLco im-
proved significantly from earlier declines post-BMT;
however FEV1 and FVC reductions remained signifi-
cantly below pretransplant values.Posttransplant PFTs and Clinical Correlates
PFT findings at 3 months post-BMT were corre-
lated with clinical outcomes posttransplant (Table 6).
Mean FEV1 and FVC predicted were significantly
lower in patients who developed pulmonaryTime of PFT (months)
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Figure 2. Changes in PFTs over time in 20 patients with PFT data at
pretransplant, 3, 6, 12, and 24 months.complication, and those with early respiratory failure.
TLC and DLco were also significantly lower in pa-
tients who developed early respiratory failure. FEV1
was significantly lower in patients who received non-
TBI (busulfan [Bu]-based) versus those who received
TBI conditioning. FEV1 and FVC were significantly
higher in those with aGVHD versus those without
aGVHD. There was no correlation between post-
transplant PFTs and risk of cGVHD or OS.DISCUSSION
The data presented in this study show that develop-
ment of PCs after allo-BMT is associated with poor out-
come in children. This appears to be particularly true for
those with early PC (occurring within 100 days of allo-
BMT) with about 1.7 times higher risk of mortality,
which translated into over 3-fold reduction in 10-year
probability of OS. A majority of patients who died
from transplant-related complications suffered from 1
or more PC (97%). Case fatality rate was high in patients
with IPS (56%). Clinical outcomes among patients with
IPS after conventional BMT have been uniformly poor,
with estimated 60% to 80% mortality rates regardless of
therapy and over 95% for those requiring mechanical
ventilation (reviewed in Cooke et al. [16]).
Thirty-nine percent of patients required mechani-
cal ventilation, and 70% of them remained ventilator-
dependent until time of death. Although median days
of mechanical ventilation was longer in nonsurviving
patients (10 versus 2 days), this difference was not sta-
tistically significant; this may be because of the small
number of extubated patients in our study. It would
be of interest to see if future studies may indicate
a time at which further mechanical ventilation may be
deemed futile. Warwick and colleagues [26] in an ear-
lier study analyzed 196 BMT recipients\19 years of
age who underwent mechanical ventilation with
Table 5. Changes in Pulmonary Function Tests over time
(n 5 20)
P Values
FEV1 Pre-BMT 3 Months 6 Months 12 Months
Pre-BMT 97 ± 20
3 months 77 ± 24 .0001
6 months 79 ± 22 .0001 .50
12 months 89 ± 22 .004 .003 .02
24 months 91 ± 20 .007 .001 .004 .34
P Values
FVC Pre-BMT 3 Months 6 Months 12 Months
Pre-BMT 99 ± 17
3 months 80 ± 24 .0001
6 months 82 ± 22 .0001 .45
12 months 92±21 .001 .01 .03
24 months 92 ±22 .006 .006 .008 .55
P Values
TLC Pre-BMT 3 Months 6 Months 12 Months
Pre-BMT 96 ± 15
3 months 82 ± 17 .001
6 months 86 ± 15 .003 .12
12 months 93 ± 15 .078 .007 .01
24 months 92 ± 15 .32 .003 .01 .91
P Values
DLco Pre-BMT 3 Months 6 Months 12 Months
Pre-BMT 75 ± 28
3 months 63 ± 27 .006
6 months 67 ± 19 .14 .35
12 mo 75 ± 21 .93 .05 .04
24 monnths 80 ± 16 .63 .01 .01 .32
BMT indicates bone marrow? transplantation; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity; TLC, total lung
capacity; DLco, diffusing capacity of the lungs.
Table 6. Posttransplant PFTs Predicted and Clinical
Outcomes
Total n FEV1 P FVC P TLC P DLco P
PC
No 14 .025 .016 .12 .85
Yes 32
Early respiratory failure
No 10 .015 .014 .008 .009
Yes 36
Conditioning
TBI 26 .035 .08 .55 .11
Non-TBI 20
aGVHD
No 17 .007 .018 .41 .24
Yes 29
cGVHD
No 28 .28 .31 .42 .21
Yes 18
Survival
Alive 33 .40 .54 .53 .23
Dead 13
cGVHD indicates chronic graft-versus-host disease; aGVHD, acute
graft-versus-host disease; TBI, total body irradiation; FEV1, forced expi-
ratory volume in 1 second; FVC, forced vital capacity; TLC, total lung
capacity; DLco, diffusing capacity of the lungs; PC, pulmonary complica-
tion; FPT, pulmonary function test.
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colleagues [27] reported a 60% mortality among 161
pediatric allogeneic transplant recipients requiring in-
vasive mechanical ventilation. Parimon et al. [11] found
a high mortality rate in adult patients developing early
respiratory failure and received mechanical ventilation
(359/396; 91%). Van Gestel and colleagues [28] re-
cently reported 42% case fatality rate (16/35) in
mechanical ventilation pediatric allogeneic BMT re-
cipients. Although these results need to be interpreted
cautiously given the retrospective nature of our study
and relatively small number of mechanical ventilation
patients, OS rate after mechanical ventilation has not
improved substantially over the last 2 decades.
We found microbiologic/histopathologic evidence
of infection in 54% episodes of LRTI; potential pulmo-
nary copathogens were demonstrated in 31% of cases.
About one-third of the BAL procedures revealed poten-
tial pulmonary pathogens. It is possible that some of the
bacterial pathogens from tracheal secretions in intu-
bated patients were not contributing to invasiveinfection, but represented colonization. Until recently,
it was not common practice to obtain quantitative cul-
tures of BAL, which would aid in making
that distinction. Our findings are concordant with
a recent report of large adult-pediatric series of BMT
recipients from Yanik and colleagues [29]. They
reported data on 347 BAL procedures in 300 patients;
BAL rate for allogeneic patients was 30.4%. Potential
pathogens were identified in 117 procedures (26.4%);
multiple pathogens were found in 30 of 117 (25.6%)
BAL studies. Nichols and colleagues [13] also found co-
pathogens in 29 of 55 (53%) BMT cases of parain-
fluenza-3 pneumonia. Copathogen isolation was
associated with higher case fatality rate. Our report
contrasts with von Eiff et al. [30], wherein diagnostic
bronchoscopy conferred improved outcome in adults
with hematologic malignancies. More recently, Eiken-
berry and colleagues [6] reported 46% diagnostic yield
of BAL in pediatric BMT recipients and no difference
in survival in those who underwent BAL or those
with pathogen identification. In our series, there was
a higher mortality rate in those undergoing BAL and
those with identification of microbial pathogen, sug-
gesting that diagnostic BAL was probably undertaken
in sicker patients and that our series represents high-
risk allogeneic patients.
Studies that have examined the predictive value of
pretransplant PFTs for posttransplant complications
suggest that poor lung function before transplant
increases the risk of posttransplant respiratory failure,
PC, and mortality (summarized in Chien et al [25]).
Parimon and colleagues [11], in a large retrospective
analysis of 2852 adults, found that reductions in pre-
BMT was significantly associated with risk of early
Biol Blood Marrow Transplant 15:817-826, 2009 825Lung Function in Pediatric Allogeneic BMT Recipientsrespiratory failure (396 patients; 14%) and death (359/
396; 91%). Efrati and colleagues [31] recently reported
abnormal baseline FEF25-75 combined with a high
residual volume (RV)/TLC ratio may be risk factors
for development of bronchiolitis obliterans. Our anal-
ysis demonstrates for the first time that pediatric allo-
BMT recipients with reduced pretransplant FEV1, or
FVC compared with those with normal values were
significantly more likely to develop early respiratory
failure. Mortality rate among patients who develop
early respiratory failure requiring mechanical ventila-
tion was very high (70%). This is in agreement with
previous findings in adults with risk of early mortality
[9-11]. In contrast to Parimon et al. [11], we did not
find a relationship between pretransplant DLco and
risk of early respiratory failure following transplant.
Previous pediatric studies of pulmonary function
have shown variable decline in PFTs at differing time
points and data on late follow-up is conflicting
[5,23,32-34]. This may be related to a small cohort
size with differences in patient and transplant charac-
teristics, inclusion of auto- and allo-BMT recipients,
and significant changes in supportive care over the
last decade. Leneveu and colleagues [23] described
PFT findings in 39 patients and found that after BMT,
FVC, TLC, and FEV1 were significantly lower at 100
days compared with pre-BMT data. The observed
respiratory abnormalities were not clinically relevant,
and no subsequent PFTs were available. Cerveri and
colleagues [32], in a study of 50 children, found signif-
icant reduction in mean FVC and DLco at 3 to 6
months after BMT; these values tended to recover pro-
gressively, although at 12 months and 24 months after
BMT, they still remained more negative than the pre-
transplant values [32]. At the time of BMT, the most
common alteration in pulmonary function was an
isolated impairment of DLco, whereas at both 3 to 6
months and 1 year after transplantation, a restrictive
pattern was the most frequent abnormality. Our study
represents a fair-sized cohort of pediatric allo-BMT
patients with pretransplant baseline and adequate post-
transplant PFT data obtained at regular scheduled in-
tervals and clinical outcomes for correlative analyses.
The results of the current study are in general agree-
ment with and extend the findings reported by Cerveri
and colleagues. PFT abnormalities were common
before BMT and isolated reduction in DLco noted
in 36% patients. Posttransplant PFTs showed signifi-
cant reductions in FVC, FEV1, TLC, and DLco at
3 and 6 months; at 12 to 24 months, these abnormalities
in FEV1, FVC, TLC, and DLco improved significantly
from earlier declines post-BMT; however FEV1 and
FVC reductions remained significantly below pre-
transplant values. Unlike Cerveri et al. [32], we ob-
served abnormalities in all lung function parameters
and did not see a predominant restrictive pattern at
these time points.In conclusion, an important finding emerging
from this study is that pretransplant PFT abnormali-
ties correlate with risk of early respiratory failure, but
not directly with OS. The observed relationship
between pretransplant FEV1 and FVC and develop-
ment of respiratory failure would need validation in
larger prospective studies, and these data may be useful
in identifying children for whom the risk of respiratory
failure and mortality with standard (myeloablative)
BMT is so high that alternative treatment options
such as RIC should be considered.ACKNOWLEDGMENTS
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